INSULIN LISPRO INJECTION, USP
UNITS PER ML (U-100)
Humalog® (insulin lispro, rDNA origin) is a human insulin analog that is a rapid-acting, parenteral blood glucose-lowering agent.
Humalog is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Humalog has a more rapid onset and a shorter duration of action than human regular insulin. Therefore, in patients with type 1 diabetes, Humalog should be used in regimens that include a longer-acting insulin. However, in patients with type 2 diabetes, Humalog may be used without a longer-acting insulin when used in combination therapy with sulfonylurea agents.
Published Studies Related to Humalog (Insulin Lispro)
Insulin injections in relation to meals in the hospital medicine ward: comparison of 2 protocols. [2011.09.01]
OBJECTIVE: To investigate whether changing the prandial regular insulin to rapid-acting insulin analogue in hospital medicine wards improves the timing of insulin delivery in relation to meals and improves patient safety and glucose control... CONCLUSIONS: The use of prandial insulin analogues in medicine wards allows better timing with meals than regular insulin and results in better hypoglycemic outcomes. Higher rates of hyperglycemia with prandial analogues may need adjustment in insulin doses.
Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor alpha are attenuated by prandial + basal insulin in patients with Type 2 diabetes. [2011.09]
AIM: To determine if a regimen with prandial + basal insulin compared with basal insulin attenuates post-meal inflammatory and glycative biomarkers in patients with Type 2 diabetes... CONCLUSIONS: Controlling post-meal hyperglycaemia with prandial + basal insulin in patients with Type 2 diabetes attenuates meal-induced increases in high-sensitivity C-reactive protein, interleukin-6 and tumour necrosis factor alpha compared with basal insulin. The rise in post-meal glucose, but not triglycerides, significantly correlated with the rise in post-meal inflammatory and glycative biomarkers. (c) 2011 The Authors. Diabetic Medicine (c) 2011 Diabetes UK.
Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. [2011.06]
BACKGROUND: In a previous pilot study comparing insulin glulisine (GLU) with insulin aspart (ASP) administered by continuous subcutaneous insulin infusion (CSII), GLU-treated patients did show a trend toward fewer catheter occlusions compared with ASP-treated patients. Here we performed a randomized open-label, three-way crossover, controlled multicenter study comparing GLU with ASP and insulin lispro (LIS)... CONCLUSIONS: GLU was not superior to ASP and LIS with no significant difference seen among GLU, ASP, and LIS in CSII use with respect to unexplained hyperglycemia and/or perceived catheter set occlusion. GLU was associated with a higher frequency of symptomatic hypoglycemia, possibly because of slight overdosing, as previous trials suggested lower insulin requirements when GLU is initiated in type 1 diabetes.
Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. [2011.04]
CONCLUSIONS: PPG with RHI administered ID via microneedle was improved versus SC delivery when dosed 17 min premeal. ID RHI provided similar control of PPG as SC IL immediately premeal. Further studies of ID insulin delivery via steel microneedles are warranted.
Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. [2011.03]
BACKGROUND: We compared the efficacy and safety of insulin glulisine with insulin lispro as part of a basal-bolus regimen in children and adolescents with type 1 diabetes... CONCLUSIONS: Glulisine was as effective as lispro in baseline-to-endpoint A1c change, and both treatments were similarly well tolerated.
Clinical Trials Related to Humalog (Insulin Lispro)
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 1 Diabetes Mellitus [Recruiting]
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus [Recruiting]
A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog´┐Ż) [Recruiting]
The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to
insulin lispro (Humalog«) when used as part of a basal-bolus regimen in patients with type 1
A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants [Recruiting]
BC106 is a molecule that when injected with insulin lispro may change the speed of
absorption of insulin lispro. The purpose of this study will be to evaluate the safety of
BC106 insulin lispro and any side effects that might be associated with it, blood levels of
insulin lispro after injection under the skin and how BC106 insulin lispro affects blood
sugar after injection under the skin. There is a minimum 7 day washout between single doses.
Comparison of Insulins Aspart and Lispro in Insulin Pumps [Active, not recruiting]
The purpose of the study is to study compare the glycemic control between insulins aspart and
lispro 48 to 100 hours after pump infusion line change in subjects with type 1 using diabetes
using an insulin pump.
Reports of Suspected Humalog (Insulin Lispro) Side Effects
Blood Glucose Increased (353),
Drug Ineffective (122),
Blood Glucose Decreased (99),
Incorrect Dose Administered (74),
Drug Dose Omission (67),
Blindness (60), more >>